Ever Supreme Bio Technology Co., Ltd. (6712) Stock Statistics & Valuation Metrics
Total Valuation
Ever Supreme Bio Technology Co., Ltd. has a market cap or net worth of TWD 14.52B. The enterprise value is TWD 15.26B.
- Market Cap
- TWD 14.52B
- Enterprise Value
- TWD 15.26B
Share Statistics
Ever Supreme Bio Technology Co., Ltd. has 100,488,860 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 100,488,860
- Owned by Insiders
- ―
- Owned by Institutions
- 0.33%
Financial Efficiency
Ever Supreme Bio Technology Co., Ltd.’s return on equity (ROE) is 0.28 and return on invested capital (ROIC) is 22.58%.
- Return on Equity (ROE)
- 0.28
- Return on Assets (ROA)
- 0.21
- Return on Invested Capital (ROIC)
- 22.58%
- Return on Capital Employed (ROCE)
- 0.28
- Revenue Per Employee
- 11.56M
- Profits Per Employee
- 4.88M
- Employee Count
- 88
- Asset Turnover
- 0.51
- Inventory Turnover
- 3.91
Valuation Ratios
The current PE Ratio of Ever Supreme Bio Technology Co., Ltd. is 30.96. Ever Supreme Bio Technology Co., Ltd.’s PEG ratio is -1.33.
- PE Ratio
- 30.96
- PS Ratio
- 13.05
- PB Ratio
- 5.29
- Price to FCF
- 23.58
- Price to Operating Cash Flow
- 23.58
- PEG Ratio
- -1.33
Income Statement
In the last 12 months, Ever Supreme Bio Technology Co., Ltd. had revenue of 1.02B and earned 429.43M in profits. Earnings per share was 4.88.
- Revenue
- 1.02B
- Gross Profit
- 721.33M
- Operating Income
- 439.00M
- Pretax Income
- 524.33M
- Net Income
- 429.43M
- EBITDA
- 462.17M
- Earnings Per Share (EPS)
- 4.88
Cash Flow
In the last 12 months, operating cash flow was 631.54M and capital expenditures -937,000, giving a free cash flow of 630.61M billion.
- Operating Cash Flow
- 631.54M
- Free Cash Flow
- 630.61M
- Free Cash Flow per Share
- 6.27
Dividends & Yields
Ever Supreme Bio Technology Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of 2.20%
- Dividend Per Share
- ―
- Dividend Yield
- 2.20%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 4.24%
- Earnings Yield
- 3.12%
Stock Price Statistics
- Beta
- 0.40
- 52-Week Price Change
- -6.34%
- 50-Day Moving Average
- 156.01
- 200-Day Moving Average
- 144.81
- Relative Strength Index (RSI)
- 28.58
- Average Volume (3m)
- 260.80K
Important Dates
Ever Supreme Bio Technology Co., Ltd. upcoming earnings date is ―, TBA (Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Ever Supreme Bio Technology Co., Ltd. as a current ratio of 1.78, with Debt / Equity ratio of 2.54%
- Current Ratio
- 1.78
- Quick Ratio
- 1.60
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.40
- Interest Coverage Ratio
- 478.73
Taxes
In the past 12 months, Ever Supreme Bio Technology Co., Ltd. has paid 94.90M in taxes.
- Income Tax
- 94.90M
- Effective Tax Rate
- 0.18
Enterprise Valuation
Ever Supreme Bio Technology Co., Ltd. EV to EBITDA ratio is 26.40, with an EV/FCF ratio of 23.08.
- EV to Sales
- 12.77
- EV to EBITDA
- 26.40
- EV to Free Cash Flow
- 23.08
- EV to Operating Cash Flow
- 23.05
Balance Sheet
Ever Supreme Bio Technology Co., Ltd. has TWD 1.06B in cash and marketable securities with TWD 232.54M in debt, giving a net cash position of TWD 824.75M billion.
- Cash & Marketable Securities
- TWD 1.06B
- Total Debt
- TWD 232.54M
- Net Cash
- TWD 824.75M
- Net Cash Per Share
- TWD 8.21
- Tangible Book Value Per Share
- TWD 15.50
Margins
Gross margin is 77.23%, with operating margin of 46.92%, and net profit margin of 40.74%.
- Gross Margin
- 77.23%
- Operating Margin
- 46.92%
- Pretax Margin
- 51.67%
- Net Profit Margin
- 40.74%
- EBITDA Margin
- 48.39%
- EBIT Margin
- 46.92%
Analyst Forecast
The average price target for Ever Supreme Bio Technology Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 13.26%
- EPS Growth Forecast
- -15.91%
